Safety-Related Labeling Changes

Serious hyper sensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving upadacitinib. If a clinically significant hypersensitivity reaction occurs, discontinue upadacitinib and institute appropriate therapy. Serious hypersensitivity reactions

Trade Name

Rinvoq

Updated Section

4.4. Special warnings and precautions for use 4.8. Undesirable effects

Month

Dec,2022